Almac Pharma Services Appoints New Director of Manufacturing Science and Technology

Almac Pharma Services Appoints New Director of Manufacturing Science and Technology

April 4, 2024

Craigavon, UK – 4 April 2024 – Almac Pharma Services, a member of the privately owned Almac Group providing innovative pharmaceutical development, manufacture and commercial services to global pharmaceutical and biotech organizations, has announced the appointment of Terry Ernest as its new Director of Manufacturing Science and Technology.  

Terry has extensive experience within the pharmaceutical development and manufacturing industry, including a deep knowledge of a variety of dose forms including modified release formulations, tablets, capsules, oral liquids and sterile liquids.

A Chartered Biologist with a Masters Degree in Industrial Pharmacy and PhD in Pharmaceutics, Terry joins Almac from GSK where he held a number of senior positions over his 30 year tenure, including his most recent role as Director, Product Development at its site in Ware, UK.

As a subject matter expert in age-appropriate drug development, Terry is a member of several pediatric focus groups in addition to multiple product development industry bodies and has published a number of papers on the topic. He has also been invited to deliver technical presentations at global conferences and industry events throughout the last 20 years.

James Hurst, VP Operations & Charnwood Site Head, commented on Terry’s appointment “We are delighted to welcome Terry to our team of established experts. His vast experience and product development expertise will provide additional technical support to our growing client base. His appointment comes at an exciting time as we proceed with our strategic growth plans by investing in our facilities, technology and our most vital asset, our people, as we continue to offer our clients, and ultimately patients across the world, a best-in-class service offering.”

Terry’s appointment comes just weeks after Almac Pharma Services announced the completion of a custom-built, high-volume facility significantly increasing its commercial manufacturing and packaging capacity, forming part of the Group’s ongoing global expansion investment program totalling £400m.


About Almac Pharma Services

Tailormade pharmaceutical development and commercial solutions

With over 50 years’ experience, Almac Pharma Services is a world leading outsourcing partner to the global pharmaceutical and biotechnology industry.  

Employing over 1,600 highly skilled individuals across 4 locations in Europe and the US, the company provides tailored, quality-led and timely solutions from early and late phase pharmaceutical development, clinical and commercial drug product manufacture, product launch through to commercial packaging and global distribution.

To keep up to date with latest news, follow us on LinkedIn or visit our website

About Almac Group  

The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialization, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture. 

The international company is a privately owned organization which has grown organically, now employing 7,200 highly skilled personnel across 18 facilities including Europe, the USA and Asia. 

To keep up to date with latest news, follow us on X and LinkedIn or visit  


Back to news